Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
Level 4 - case-series / case-control
Uncontrolled clinical pilot case series
PubMed 16113597 · doi:10.1159/000087608
What was done
A pilot study evaluated a modified administration protocol for poly-L-lactic acid (PLA; New-Fill/Sculptra) using higher dilution and deeper subcutaneous injection in 14 HIV-infected patients experiencing facial lipoatrophy from highly active antiretroviral therapy (HAART). Injections were administered at intervals of approximately 2 to 3 weeks.
What was found
The abstract provides no numerical data, variance values, or statistical test results. Qualitatively, the authors reported that treatment efficacy remained comparable to previous protocols while tolerability improved and nodule formation became a minor problem. Increases in facial dermal thickness were described as most noticeable in patients with a shorter duration of lipoatrophy.
Why it matters
Altering the dilution and injection depth of poly-L-lactic acid may minimize adverse nodule formation while retaining cosmetic efficacy in HAART-associated facial lipoatrophy.
Limits
The study is a very small (n = 14), uncontrolled case series. The abstract reports no quantitative measurements, statistical comparisons, or long-term follow-up data.
Cited by
- supports Sculptra was originally FDA-approved over 21 years ago for the treatment of facial lipodystrophy in HIV patients.